Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden heart inflammation early

NCT ID NCT05499637

Diagnosis Sponsor: John O. Prior Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a special PET/CT scan using a tracer called PentixaFor can accurately detect acute inflammation in the heart. It focuses on three conditions: heart transplant rejection, cardiac sarcoidosis, and myocarditis caused by cancer drugs. Researchers will enroll 69 adults to compare the scan results with standard diagnostic methods. If successful, this could lead to a non-invasive way to diagnose heart inflammation earlier.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 69 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * signed written informed consent * male or female * age ≥ 18 years * patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I) * SOC clinical follow-up at the cardiology department in CHUV. Exclusion Criteria: The presence of any one of the following exclusion criteria will lead to exclusion of the participant: * absence of a signed written informed consent * patients aged \< 18 years * claustrophobia * myocardial ischemia in non-invasive perfusion test or coronarography in group II and III * clinically unstable cardiovascular conditions, including: * clinically unstable brady-tachyarrhythmia * severe and symptomatic hypo- or hypertension with documented systolic blood pressure \< 90 mmHg or ≥220 mmHg respectively * cardiogenic shock. * women who are pregnant or breast feeding * intention to become pregnant during the course of the study in group II * previous enrolment into the current study * moderate to severe renal insufficiency (GFR \< 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III * enrollment of the investigator, his/her family members, employees and other dependent persons * history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment * insufficient knowledge of project language, inability to give consent or to follow procedures * the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute cellular graft rejection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute transplant rejection cardiac sarcoidosis toxic myocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute cellular graft rejection Cardiac sarcoidosis Myocarditis due to drug

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.